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Abstract
Introduction: Although the prognostic significance of proliferation in early invasive breast cancer has been
recognized for a long time, recent gene-expression profiling studies have reemphasized its biologic and prognostic
value and the potential application of its assessment in routine practice, particularly to define prognostic
subgroups of luminal/hormone receptor-positive (HR+) tumors. This study aimed to assess the prognostic value of
a proliferation assay by using Ki-67 immunohistochemistry as compared with mitotic count scores.
Method: Proliferation was assessed by using Ki-67 labeling index (Ki-67LI) and mitotic scores in a large (n = 1,550)
and well-characterized series of clinically annotated primary operable invasive breast cancer with long-term follow-
up. Tumors were phenotyped based on their IHC profiles into luminal/HR+, HER2+, and triple-negative (TN) classes.
We used a split-sample development and validation approach to determine the optimal Ki-67LI cut-offs.
Results: The optimal cut-points of Ki-67LI were 10% and 50% for the luminal class. Both Ki7LI and MS were able to
split luminal tumors into subgroups with significantly variable outcomes, independent of other variables. Neither
mitotic count scores nor Ki-67LI was associated with outcome in the HER2+ or the TN classes.
Conclusions: Assessment of proliferation by using Ki-67LI and MS can distinguish subgroups of patients within
luminal/hormone receptor-positive breast cancer significantly different in clinical outcomes. Overall, both Ki-67 LI
and mitotic-count scores showed comparable results. The method described could provide a cost-effective method
for prognostic subclassification of luminal/hormone receptor-positive breast cancer in routine clinical practice.
Introduction
Tumor proliferative activity represents one of the most
thoroughly investigated cellular functions in breast can-
cer (BC) for its association with tumor behavior [1].
Assessment of proliferation rates has been shown to
provide useful information on prognosis and aggressive-
ness of individual cancers and can potentially be used to
guide treatment protocols in clinical practice. Recently,
a meta-analysis of publicly available breast cancer gene-
expression signatures has identified proliferation as the
key biologic driver in all nine prognostic signatures
included in the study [2]. It was also demonstrated that
the assignment of basal-like and ERBB2+ (HER2+) breast
cancers to the poor-prognosis groups by first-generation
gene signatures is determined mainly by high expres-
sions of proliferation-related genes [2,3]. Moreover, it
has been reported that expression of genes involved in
cell proliferation is the most heavily weighted compo-
nent in calculating the recurrence score [4] and is the
basis of genomic grading [5,6].
Various techniques have been developed to quantify
proliferation rates, including, mitotic-count estimates,
measurement of DNA synthesis, and flow cytometry
[1,7-9]. Newer techniques include detection of antigens
closely associated with proliferation by using immuno-
histochemistry (IHC). In theory, the latter methods are
quicker, cheaper, and easier to use than flow cytometry
and autoradiography and are more reproducible than is
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mitotic figure counting [7]. Although most studies of
different proliferation assays displayed significant agree-
ment in outcome predictions for individual patients, no
consensus exists on the best proliferation assay [10].
Mitotic-count scores (MSs) are used in routine BC his-
tologic grading, and the prognostic significance is well
established [11,12]. Immunohistochemical expression of
Ki-67 is now widely used as an IHC measure of prolif-
eration [13-15]. Although Ki-67 is not yet incorporated
into routine pathology practice, its use in proliferation
assays in translational studies has yielded promising
results [16-18]. Several studies have sub-classified lumi-
nal tumors (that is, estrogen receptor (ER)-positive,
HER2 negative) based on differential expression of pro-
liferation-associated genes “proliferation signature,”
gene-expression profiling (GEP), or by Ki-67 in IHC stu-
dies [16,17,19]. However, some technical and validation
issues are to be addressed before Ki-67 is used in BC
routine practice. It remains to be determined whether
Ki-67 IHC outperforms mitotic counting as a predictor
of outcome. Moreover, evidence of the prognostic value
of using MS in an algorithm for defining molecular BC
classes is yet to be elucidated.
Consequently, this study was conducted on a large,
well-characterized series of early (stage I through III)
invasive BC with long-term follow-up to study the prog-
nostic value of MS and Ki-67LI, as methods of prolifera-
tion assays, in different BC molecular classes. We used a
split-sample development and validation approach to
determine the optimal Ki-67LI cut-offs and demon-
strated its prognostic relevance in the validation cohort
in luminal/HR+, HER2+, and triple-negative tumors.
Materials and methods
Patients and tumors
This study was based on a well-characterized cohort of
early-stage (I-III) primary operable invasive BC from
patients aged 70 years or younger, enrolled into the
Nottingham Tenovus Primary Breast Carcinoma Series
between 1990 and 1998 (n = 1,550), and managed in
accordance with a uniform protocol. Patients’ clinical
history, tumor characteristics, and information on ther-
apy and outcomes are prospectively maintained. Out-
come data include survival status, survival time, cause of
death, development, and time to locoregional recurrence
and distant metastasis (DM). Breast Cancer Specific Sur-
vival (BCSS) is defined as the time (in months) from the
date of primary surgery to the date of breast cancer-
related death. DMFS is defined as the time (in months)
from the date of primary surgery to the appearance of
distant metastasis.
Patients had a median age of 54 years (range, 18 to 70
years) with a median overall survival of 123 months
(range, 4 to 234 months) and a median time of event-
free survival of 110 months (range, 3 to 226 months).
Distant recurrence occurred in 443 (30.4%) cases; 392
(26.9%) patients died of BC; and 747 (58.1%) patients
were alive at the end of follow-up.
Assessment of mitotic counts
Mitotic figures were counted by one of three patholo-
gists with extensive experience in BC histopathology
from Nottingham City Hospital, Nottingham, UK (Ian
Ellis, Sarah Pinder, and Christopher Elston), in 10 high-
power fields, as part of routine BC histologic grading
[20]. Scores of 1 to 3 were used, with cut-off points
determined based on association with outcome (MS 1, ≤
9 mitoses/10 hpf; MS 2, 10 to 19 mitoses/10 hpf; and
MS 3, ≥ 20 mitoses/10 hpf) by using a 0.59-mm micro-
scopic field diameter [21].
Ki-67 immunohistochemistry
Formalin-fixed paraffin tissue sections (FFSs, 4 μm)
mounted on Superfrost slides (Surgipath) were immuno-
histochemically stained, by using the standard streptavi-
din-biotin complex method, as previously described
[22]. Microwave-assisted heat-induced retrieval method
for antigen epitopes was performed in citrate buffer, at
pH 6.0 for 20 minutes. Endogenous peroxidase activity
was blocked by incubation in a 0.3% hydrogen peroxide
in methanol buffer for 10 minutes. Nonspecific binding
of primary antibody was blocked by using normal swine
serum (NSS, in Tris-buffered saline (TBS) (1:5), 100 μl/
slide) for 10 minutes of incubation. Primary mouse
monoclonal anti-Ki-67 antibody (MIB1 clone, product
M7240; Dako, Glostrup, Denmark), diluted 1:100 (opti-
mum working dilution) in NSS/TBS, was applied to
each slide and incubated for 60 minutes at room tem-
perature. Slides were then rinsed in TBS before staining
with a streptavidin-biotin three-stage technique, with
the Dako Strept ABC complex/HRP Duet kit (Dako,
K492) according to manufacturer’s guidelines. For reac-
tion visualization, 3-3 diaminobenzidine tetrahydrochlor-
ide (Dako liquid DAB Plus, K3468) was used as
chromogen. The sections were counterstained with
Mayer hematoxylin (Dako, AR106). Human tonsil sec-
tions were used as positive control, whereas negative
control was performed by replacing the primary anti-
body by TBS. These controls were included in each
staining run. Additionally, to assess the optimal number
of tumor blocks from an individual case sufficient to
report on Ki-67LI, four FFSs cut from four different par-
affin blocks, representative of 25 invasive BC cases, also
were stained.
Ki67 scoring
Immunostaining was quantitatively evaluated by using
light microscopy, in which the entire section was
scanned at low-power magnification (×100) to
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determine areas with the highest numbers of positive
nuclei (hot spot) within the invasive component [22].
These were usually found at the periphery of tumors
and were easier to identify than the mitotic figure hot
spots. Ki-67 labeling index (Ki-67LI) was expressed as
the percentage of MIB1-positive cells among a total
number of 1,000 malignant cells at high-power magnifi-
cation (×400). A randomly chosen subset of cases (n =
200) was rescored by the same observer (MA), and an
intraobserver reproducibility test was performed (kappa
value, 0.85).
Definition of molecular classes
Data on a wide range of biomarkers of known clinical
and biologic relevance to BC were available, including
hormone receptors [HR, ER, and progesterone receptor
(PR)], epidermal growth factor-receptor family members
(HER1 (EGFR), and HER2) and basal cytokeratins (CKs)
(CK5/6 and CK14) [23,24]. In this study, HER2 was
assessed by using IHC and dual-color chromogenic in
situ hybridization (CISH), as previously published [25].
Moreover, data on a subset of 128 frozen BC tissues that
were profiled by using Illumina WG-6 BeadChips, as pre-
viously described [26], was available. These expression
data are available at the EBI website http://www.ebi.ac.
uk/miamexpress/ with E-TABM-576 accession number.
Molecular classes were defined as luminal (HR+: ER+
and/or PR+]), HER2+ (HER2+ regardless of the expres-
sion of other markers), basal-like [BLBC] (ER-, PR-,
HER2-, and positive for CK5/6, and/or CK14 and/or
EGFR), and triple-negative nonbasal BC (TNnon-B; all
these markers negative) [23,27].
To assess the optimal Ki-67 LI cut-off in different
molecular classes and to avoid data overfitting, each
molecular class was randomly split into two subsets by
using SPSS random sampling; one third of cases were
used as a training set, and the remaining two thirds
used as a validation (test) set. No differences between
training and validation sets were identified in any of the
molecular classes (Table 1).
Table 1 Clinicopathologic features of the whole
Characteristics Whole series Luminal class HER2+ class Triple-negative class
Training
No (%)
Validation
No (%)
P Training
No (%)
Validation
No (%)
P Training
No (%)
Validation
No (%)
P
Age
Median (Range) 54 (18-70) 55 (18-70) 55 (28-70) 0.690 52 (29-69) 52 (27-70) 0.657 49.5 (29-70) 50 (27-70) 0.885
Menopausal status
Premenopausal 571 (39.2) 116 (36.7) 232 (35.6) 0.887 31 (47.7) 58 (45.3) 44 (54.8) 90 (56.3) 0.892
Postmenopausal 886 (60.8) 200 (63.3) 419 (64.4) 34 (52.3) 70 (57.7) 0.762 36 (45.1) 70 (34.8)
Tumor grade
Grade I 255 (17.5) 80 (25.3) 151 (23.2) 2 (3.1) 5 (3.9) 3 (3.6) 1 (0.6) 0.892
Grade II 479 (32.9) 141 (43.9) 282 (43.3) 0.371 8 (12.3) 25 (19.5) 0.417 7 (8.3) 8 (5.0)
Grade III 723 (48.6) 95 (29.6) 218 (33.5) 55 (84.6) 98 (76.6) 70 (88.1) 151 (94.4)
Tumor size
≤ 2 cm 899 (61.8) 215 (68.1) 433 (66.5) 0.561 40 (61.5) 77 (60.2) 0.877 42 (52.5) 71 (44.4) 0.180
> 2 cm 556 (38.2) 101 (31.9) 218 (33.5) 25 (38.5) 51 (39.8) 38 (47.5) 89 (55.6)
Tumor type
Ductal, no special type 853 (58.5) 159 (50.3) 331 (50.8) 0.874 59 (90.8) 112 (88.2) 0.807 70 (87.5) 136 (86.1) 1.00
Other histologic types 604 (41.5) 157 (49.7) 320 (49.2) 6 (9.2) 15 (11.8) 12 (12.5) 22 (13.9)
NPIa
Good 457 (31.4) 141 (44.6) 275 (42.2) 4 (6.5) 16 (12.5) 7 (8.6) 13 (8.1)
Moderate 767 (52.6) 145 (45.9) 295 (45.3) 0.312 47 (72.3) 78 (60.9) 0.226 55 (68.9) 109 (68.1) 0.417
Poor 233 (16.0) 30 (9.5) 81 (12.4) 14 (21.5) 34 (26.6) 18 (22.5) 38 (23.8)
Mean (range) 3.4 (2.04-5) 3.42 (2.05-5) 3.43 (2.06-5) 4.7 (2.6-5) 4.7 (2.6-5) 4.51 (2.05-5) 4.52 (2.05-5)
Recurrence
Local: No 1,249 (89.0) 283 (89.6) 588 (90.3) 55 (84.6) 108 (84.4) 70 (87.5) 136 (85.0) 0.564
Yes 160 (11.0) 33 (10.4) 63 (9.7) 0.819 10 (15.4) 20 (15.6) 1.000 10 (12.5) 24 (15.0)
Regional: No 1,280 (91.0) 291 (92.1) 594 (91.2) 58 (89.2) 112 (87.5) 70 (87.5) 147 (91.9) 0.259
Yes 129 (9.0) 25 (7.9) 57 (8.8) 0.713 7 (10.8) 16 (12.5) 0.817 10 (12.5) 13 (8.1)
Distant: No 1,014 (69.6) 239 (75.6) 473 (72.7) 0.278 34 (52.3) 71 (55.5) 50 (62.5) 107 (66.9) 0.573
Yes 443 (30.4) 77 (24.4) 178 (27.3) 31 (47.7) 57 (44.5) 0.760 30 (37.5) 53 (33.1)
aSeries (n = 1,457), training sets, and validation sets of luminal, HER2+ (n = 193), and TN (n = 244) molecular BC classes Nottingham Prognostic Index. Good
Prognostic Group, ≤ 3.4; Moderate Prognostic Group, 3.41 to 5.4, Poor Prognostic Group, > 5.4
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Statistical analysis
Statistical analysis was performed by using SPSS 15.0
statistical package (SPSS Inc., Chicago, IL, USA). X-tile
software (version 3.6.1, 2003-2005, Yale University, New
Haven, CT, USA) [28] was used to de-termine the opti-
mal Ki-67LI cutoff point(s) in different molecular sub-
types. Correlations between Ki-67LI and MS and other
variables were studied with a c2 test, Fisher Exact test,
and Mann-Whitney U test. Survival curves for BCSS
and DMFS were drawn by using the Kaplan-Meier esti-
mates, and significance was assessed by using log-rank
tests. Multivariate analyses of BCSS and DMFS were
conducted by using Cox proportional hazard regression
models. A two-tailed P value < 0.05 was considered
significant.
This study was approved by the Nottingham Research
Ethics Committee 2 under the title “Development of a
molecular genetic classification of breast cancer.” All
patients who participated in this study gave their written
informed consent at the time of their donation.
Results
In the current study, informative results for Ki-67LI,
MS, and follow-up data were available for 1,457 cases
(94% of the whole series). To assess the optimal number
of FFSs sufficient to report Ki-67LI reliably, four FFSs
were cut from four different paraffin blocks representa-
tive of 25 invasive BC cases. These showed high levels
of concordance between sections when Ki-67LI was ana-
lyzed as continuous variable (P < 0.0001; Table 2) and
when categorized by using different cut-off points
(kappa value, 0.834; 95% CI, 0.76 to 0.92), indicating
that one FFS is sufficient for reliable Ki-67LI assessment.
Significant association was observed between Ki-67LI
and MKI67 gene transcript, as defined by microarray-
based gene-expression profiling (r2 = 0.24; P < 0.0001),
and between Ki-67LI and MS (P < 0.0001). High Ki-
67LI and MS were associated with premenopausal sta-
tus, larger tumor size, definite vascular invasion, and
lymph node involvement (P < 0.0001). Significant differ-
ences appeared between BC molecular classes regarding
their Ki-67LI (ANOVA, F = 167; P < 0.0001) (Figure 1).
Bonferroni post hoc testing of Ki-67LI revealed
significant differences between luminal (lowest Ki-67LI)
and HER2+ (intermediate Ki-67LI) and between HER2+
and triple-negative (highest Ki-67LI) classes. However,
the difference between BLBC and TNnon-B was not sig-
nificant (P = 0.263). Similar results were found when
MS was used to define proliferation. When the prognos-
tic results of Ki-67LI were expressed as a continuous
variable in the class of luminal ER+/HER2- tumors, this
showed association with outcome (c2 = 80; P < 0.0001;
HR = 1.1; 95% CI, 1.0 to 1.2). Moreover, Ki-67LI cut-
offs at 10% increments within the same class showed
statistically significant differences between the resulting
patients’ subsets (LR = 142.64; P < 0.0001; HR = 1.3;
95% CI = 1.2 to 1.3; Figure 2).
Determination of the optimal Ki-67LI cut-offs
In the training sets, the prognostic significance of pre-
viously defined Ki-67LI cut-off points including 10%,
13%, 17% (median), 20%, 25%, 30%, 35% [16,27,29,30]
were assessed (Table 3). This shows that 10% cut-off
had the highest hazard ratios in the luminal class, but
none of these cut-offs was statistically significant in
HER2+ or TN classes. The optimal Ki-67LI cut-offs
within each molecular class was then assessed by using
X-tile software analysis [28]. In the luminal class, this
showed that 10% is the optimal cut-off separating low
from moderate/high proliferative subgroups. In addition,
it showed that 50% cut-off value can split the latter sub-
group into two prognostically different subclasses (mod-
erate (10% to 50%) and high proliferative subgroups (>
50%)) with a reasonable number of cases within each
subclass (Figure 3). In HER2+ and TN classes, only one
cut-off could be identified (75% and 70%, respectively).
Table 4 displays MS, training and validation sets, and
Ki-67LI cut-off points in BC molecular classes.
Proliferation in luminal class
Univariate survival analysis of the validation set revealed
significant association between MS (1, 2, and 3) and
patients’ outcomes, including BCSS (P < 0.001, HR = 2.3;
95% CI = 1.9 to 2.8), and DMFS (P < 0.001; HR = 1.9; 95%
CI, 1.6 to 2.3). Low, moderate, and high proliferative sub-
groups of luminal class validation set displayed significant
Table 2 Results of multivariate analysis of variance (MANOVA) test for Ki-67LI assessed on FFS from 25 invasive BC
cases
Factor Mean Ki-67LI Standard error 95% confidence interval MANOVA P value
Lower bound Upper bound
Section 1 71.280 4.701 62.376 81.184 14.960 < 0.0001
Section 2 74.800 4.034 66.475 83.125
Section 3 71.800 4.709 62.082 81.518
Section 4 74.160 4.054 65.793 82.527
Presented as one section per block; four sections per case.
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differences in BCSS (LR = 76.75; P < 0.001; HR = 2.5; 95%
CI, 2.0 to 3.2) and DMFS (LR = 90.87; P < 0.001; HR =
2.2; 95% CI, 1.8 to 2.7) (Figure 4). Multivariate analysis
showed that both MS and Ki-67LI were independent prog-
nostic factors (P < 0.001). However, the HR for Ki-67LI
was slightly higher than that of MS, although the CIs of
the high-proliferation subgroups overlapped. As Ki-67LI
and MS are highly correlated, multivariate analysis includ-
ing MS, tumor grade, nodal stage, and tumor size was
repeated after the addition of Ki-67LI. This showed that
Ki-67LI has a higher HR than that of MS for both BCSS
and DMFS; Table 5.
Interestingly, the HRs for both BCSS and DMFS were
highest for Ki-67LI, followed by histologic grade, HER2
status, and then by MS, whereas the lowest HR was
achieved by PR status; Table 6.
To assess the difference between Ki-67 and HER2 sta-
tus in HR+ cancers, luminal tumors were further classi-
fied after inclusion of HR+/HER2+ tumors [31,32] into
luminal 1 and 2, with the former being HR+ and HER2-
(luminal), and the later being HR+ and HER2+. In lumi-
nal 1 subclass, both Ki-67LI and MS were associated
with BCSS and DMFS, independent of other variables.
However, no associations were found between either
MS or Ki-67LI with BCSS or DMFS in luminal 2 sub-
class by using either 10% and 50% or 75% Ki-67LI cut-
offs. When HER2 status and proliferation were consid-
ered within HR+ tumors, distinct subclasses with prog-
nostic significance were identified (Figure 5). Ki-67LI
and MS classified HR+ tumors into low (excellent out-
come) and moderate proliferative activity (moderately
poor outcome), whereas the high-proliferative group was
associated with the worst outcome that was not different
from HER2+ tumors (Table 7). Similar results were
obtained after adjustment for chemotherapy. Multivari-
ate analysis including size, nodal stage, VI, systemic
therapy, Ki-67LI, and MS showed that Ki-67LI HR (1.6;
95% CI, 1.2 to 2.1) is similar to that of stage (1.8; 95%
CI, 1.4 to 2.2) and HER2 (1.7; 95% CI, 1.3 to 2.6), and
higher than that of MS (1.4; 95% CI, 1.1 to 1.8).
In addition, analysis of 70 luminal tumors defined by
global gene-expression profiling [26] showed significant
association between Ki-67LI and BCSS (P = 0.011; HR,
2.2; 95% CI, 1.2 to 4.1) and DMFS (P = 0.016; HR, 2.1;
95% CI, 1.1 to 3.7), and between MS and BCSS (P =
0.024; HR, 1.8; 95% CI, 1.1 to 3.1) and DMFS (P =
0.015; HR, 1.9; 95% CI, 1.1 to 3.2).
Proliferation in HER2-positive breast cancer
Kaplan-Meier plots showed no association between MS
and either BCSS (P = 0.611; HR, 1.1; 95% CI, 0.7 to 1.5)
or DMFS (P = 0.617; HR, 1.0; 95% CI, 0.7 to 1.5) in
HER2+ tumors. Combining MS1 and 2 and repeated test-
ing against MS3 yielded the same results. Although 75%
Ki-67LI cut-off split the HER2+ training set into low/
moderate (< 75%; 80% of cases) and high-proliferative (≥
75%; 20% of cases) subclasses with difference in out-
comes, survival analysis within the HER2+ validation set
showed no significant difference between these two sub-
groups for either BCSS (P = 0.445) or DMFS (P = 0.784).
Proliferation in triple-negative breast cancers
Univariate survival analysis revealed no association between
MS and either BCSS (P = 0.317) or DMFS (P = 0.590) in
TN cancers. Similarly, no difference was found when MS1
and 2 were combined and tested against MS3. In addition,
Figure 1 Box plot of Ki-67LI in different BC molecular classes,
and their corresponding levels of significance in post hoc
analysis.
Figure 2 Association between BCSS and Ki-67LI expressed in
10% increments (10% each.) However, tumors showing 50% to
69% and 80% to 100% Ki-67LI were considered as two groups,
as the number in each 10% subgroup was small). Labels 1
through 8 represent patients’ subsets based on tumor Ki-67LI, where
1 is 0 to 9%; 2 is 10% to 19%; 3 is 20% to 29%; 4 is 30% to 39%; 5 is
40% to 49%; 6 is 50% to 69%; 7 is 70% to 79%; and 8 is 80% to 100%.
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no association was found between Ki-67LI and BCSS or
DMFS by using the X-tile generated cut-point in the TN
BC training set (that is, 70%; P = 0.174). When TN tumors
were subclassified into BLBC and TNnon-B BC, Kaplan-
Meier plots showed no significant association between MS
and Ki-67I and either BCSS or DMFS (P > 0.05).
Discussion
Although the prognostic significance of proliferation in
BC has been documented and validated in several
independent studies, recent global gene-expression
profiling studies have reemphasised its biologic and
prognostic importance. Several studies have identified
the proliferation signature as a key element in the
molecular classification of BC and in the composition
of different prognostic and predictive gene signatures
[2]. Therefore, some recent studies have raised the
issue of using an immunohistochemical marker for
assessment of proliferation (for example, Ki-67) to be
used in combination with other IHC surrogate panels
used for BC molecular classification: ER, PR, and
HER2 [16,17]. These studies have demonstrated that
Ki-67LI is associated with outcome and, when used in
combination with other markers mentioned previously,
Table 3 Hazard ratios for different Ki-67LI cut-off points for BCSS and DMFS in luminal and HER+ training sets
Cut-off point Luminal BC HER2+ BC
BCSS DMFS BCSS DMFS
P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI)
10% < 0.001 4.289 (3.043-6.045) < 0.001 2.951 (2.233-3.901) 0.439 1.314 (0.658-2.625) 0.401 1.334 (0.674-2.682)
13% 3.484 (2.580-4.704) 2.595 (2.006-3.356) 0.647 0.883 (0.519-1.503) 0.758 0.920 (0.541-1.536)
17% 3.387 (2.547-4.506) 2.468 (1.923-3.166) 0.318 0.780 (0.480-1.270) 0.368 0.800 (0.493-1.299)
20% 3.555 (2.683-4.712) 2.578 (2.012-3.304) 0.367 0.805 (0.502-1.291) 0.457 0.837 (0.523-1.339)
25% 3.091 (2.348-4.069) 2.458 (1.918-3.150) 0.355 0.810 (0.519-1.265) 0.483 0.854 (0.549-1.328)
30% 3.004 (2.283-3.954) 2.415 (1.880-3.101) 0.717 0.923 (0.596-1.427) 0.824 0.952 (0.617-1.468)
35% 3.182 (2.413-4.195) 2.648 (2.055-3.413) 0.698 1.089 (0.708-1.675) 0.723 1.080 (0.706-1.652)
10% and 50%: 0.191 0.334
Moderate vs. low 3.473 (2.421-4.983) 2.483 (1.847-3.336) 0.747 1.126 (0.547-2.319) 0.611 1.205 (0.588-2.469)
High vs. low 7.648 (5.116-11.43) 5.021 (3.533-7.134) 0.188 1.638 (0.786-3.414) 0.220 1.586 (0.759-3.313)
BCSS, Breast cancer-specific survival; DMFS, distant metastasis-free survival; MS, mitosis score.
Figure 3 Kaplan-Meier survival plot for luminal BC training set using Ki-67LI and MS. (a) Breast cancer-specific survival (BCSS). (b)
Metastasis-free survival at 10% and 50% Ki-67LI cut-off point. (c, d) BCSS and DMFS for mitosis-frequency scores.
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provides valuable prognostic information and can sub-
classify luminal (HR+ tumors) into prognostically dis-
tinct subclasses. Therefore, in the current study, we
used a well-characterized series of operable invasive
BC to assess the prognostic significance of Ki-67LI
with regard to BC molecular classes compared with
that provided by the routinely assessed MS and
addressed some technical issues for use in routine
practice in assessing tumor proliferation.
The distributions of Ki-67LI values in this series (mean
and median) were consistent with those found in
previous studies [29,33], and have a significant correla-
tion with MKI67 gene transcript and MS. Consis-tent
with the results of GEP studies [2], the majority of HER2
+ and TN tumors showed high proliferative activity in
terms of high Ki-67LI and high MS, whereas up to half of
luminal BCs were of low MS and showed low Ki-67LI.
In luminal BC, proliferation assays using MS and Ki-
67LI identified subdivisions with statistically different
patient outcomes. In this group, both MS and Ki-67LI
retained their significant and independent association
with outcome and identified three subclasses; one (low-
Table 4 Mitotic scores (MSs), training and validation sets, and Ki-67LI descriptive measures in BC molecular classes
Luminal number (%) HER2+ number (%) TN number (%)
Totala 967 (69.9) 193 (13.6) 240 (16.5)
Mitosis scores
1 318 (48.8) 16 (12.5) 4 (2.5)
2 143 (22) 29 (22.7) 8 (5)
3 190 (29.2) 83 (64.8) 148 (92.5)
Training setb 316 (33) 65 (33) 80 (33%)
Validation setb 651 (67) 128 (67) 160 (67)
Ki-67LI in the validation sets
Ki-67 mean (SD) 22 (24.6) 41.5 (27.4) 64.5 (32)
Ki-67LI median (range) 11 (0-98) 39.5 (0-97) 77 (1-98)
Ki-67LI Cut-off 10 50 70 -
aThis percentage is relative to the whole patients’ series (that is, 1,457 cases). bThis percentage is relative to number of cases within the same class.
Using 10% and 50% Ki-67LI cut offs divided the luminal class into low (46.9%), moderate (41.6%), and high (11.5%) proliferation subgroups, respectively.
Ki-67LI cut-offs were generated by using X-tile software in the training sets.
Figure 4 Kaplan-Meier survival plot for luminal BC validation set using Ki-67LI and MS. (a) Breast cancer-specific survival (BCSS) and (b)
metastasis-free survival at 10% and 50% Ki-67LI cut-off point. (c, d) BCSS and DMFS for mitosis frequency scores (by using the validation set only).
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proliferative group) associated with excellent prognosis
where adjuvant chemotherapy is unlikely to provide
benefit and could potentially be withheld, and one class
(high-proliferative group) with a worse prognosis akin to
HER2+ tumors trastuzumab (Herceptin)-naïve patients)
that may be an appropriate subclass likely to benefit
from chemotherapy. These findings confirm the prog-
nostic relevance of routinely assessed MS in the luminal
class, as previously reported in BC [1,7,8]. It is, however,
important to recognize that our results relating to MS
Table 5 Cox proportional hazards analysis for predictors of BCSS and DMFS in luminal BC valida-tion set: effect of Ki-
67LI, MS, tumor grade, nodal stage, tumor size, and adjuvant therapy
Variables Luminal BC
BCSS DMFS
P value HR (95% CI) P value HR (95% CI)
Ki-67LI 0.019 0.031
Low
Moderate 0.028 1.945 (1.076-3.513) 0.258 1.319 (0.816-2.132)
High 0.005 2.679 (1.347-5.330) 0.013 2.097 (1.171-3.754)
Mitosis scores 0.028 0.015
1
2 0.043 1.403 (0.723-2.723) 0.055 1.228 (0.801-2.002)
3 0.033 2.096 (0.938-4.687) 0.018 1.854 (0.919-3.741)
Tumor grade 0.022 0.024
1
2 0.016 1.379 (0.647-2.938) 0.041 1.604 (0.878-2.930)
3 0.014 1.595 (0.621-4.096) 0.017 1.566 (0.909-3.459)
Nodal stage 0.001 0.001
Node negative
1 to 3 positive LN 0.001 1.969 (1.331-2.913) 0.003 1.839 (0.297-2.607)
≥ 4 positive LN 0.002 3.498 (2.069-5.915) 0.005 3.330 (2.070-5.358)
Tumor size 0.221 1.262 (0.869-0.834) 0.019 1.492(1.067-2.087)
Endocrine therapy (No/Yes) 0.378 0.553 (0.324-0.499) 0.961 0.998 (0.904-1.101)
Chemotherapy (No/Yes) 0.030 0.768 (0.451-0.309) 0.061 0.636 (0.397-1.021)
BCSS, Breast cancer-specific survival; DMFS, distant metastasis-free survival; MS, mitosis score.
Table 6 Cox proportional hazards analysis for predictors of BCSS in luminal BC validation set: effect of Ki-67LI, MS,
tumor grade, HER2 status, PR status, and adjuvant therapy
Variables Luminal BC
BCSS DMFS
P value HR (95% CI) P value HR (95% CI)
Ki-67LI 0.006 0.003
Low
Moderate 0.020 2.016 (1.118-3.636) 0.211 1.359 (0.840-2.198)
High 0.002 3.002 (1.522-5.923) 0.002 2.504 (1.410-4.448)
Tumor grade 0.031 0.021
1
2 0.018 1.696 (0.783-3.672) 0.055 1.817 (0.987-3.346)
3 0.023 1.736 (0.634-4.753) 0.011 1.556 (0.986-3.659)
HER2 status 0.021 1.528 (1.022-2.385) 0.042 1.263 (0.982-2.746)
Mitosis scores 0.018 0.044
1
2 0.043 1.267 (0.651-2.466) 0.013 1.292 (0.742-2.257)
3 0.086 2.113 (0.899-4.967) 0.017 1.877 (0.881-3.999)
PR status 0.030 0.635 (0.422-0.956) 0.064 0.701 (0.481-1.021)
Endocrine therapy (No/Yes) 0.886 0.992 (0.890-1.106) 0.314 1.049 (0.955-1.152)
Chemotherapy (No/Yes) 0.332 0.768 (0.451-0.309) 0.640 0.893 (0.557-1.432)
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are based on optimized and standardized methods for
tissue handling, fixation, and preparation [21]. Subopti-
mal tissue fixation has been demonstrated to affect
adversely the ability to assess mitotic frequency, result-
ing in a systematic downgrading of cases [34-36]. Criti-
cal evaluation of these issues with recommendations for
good practice has been provided by professional organi-
zations. Significant improvements in the consistency of
assessment of mitotic counts and hence histologic grad-
ing have been observed on a national basis in the United
Kingdom through publication of guidelines with linked
educational activity and associated external quality
assurance [34]. However, it is worth mentioning that the
prognostic information obtained by Ki-67LI in luminal
tumors is equivalent to or even greater (in terms of HR)
than that provided by MS alone and than that provided
by histologic grade or HER2 or PR status.
Different authorities have highlighted the prognostic
significance of Ki-67LI in luminal BC, with emphasis on
its ability to stratify patients into low-risk and high-risk
populations. Although, in these studies, luminal BCs
were subdivided into distinct subgroups, the optimal
cut-off point remains nonstandardized, with most stu-
dies using a single, usually the median, cut-off point;
dividing these tumors into two subgroups [16]. In this
study, two cut-offs for Ki-67LI (10% and 50%) were
identified as derived from associations with patient out-
come in luminal tumors, which is the largest class of
BC; three subdivisions with significantly different out-
comes with adequate numbers of cases within each sub-
group. In this study, the proliferative activity assessed by
using Ki-67LI was compared with mitotic counts that
were scored in routine practice by using full-face sec-
tions (one to four sections per tumor). Ki-67 LI was
Figure 5 Kaplan-Meier survival plot of luminal tumors showing
association between HER2 status and proliferation. (Ki-67LI, a,
and MS, b) and BCSS (LR = 88; P < 0.0001; HR, 1.683; 95% CI, 1.492
to 1.898, and LR, 90.239; P < 0.0001; HR, 1.749; 95% CI, 1. 543 to
1.982, respectively; validation set only). Number of patients at risk is
shown above the curves.
Table 7 Ten-year survival rates of hormone receptors positive (ER+ and/or PR+)/luminal class (including HER2+ cases)
based on proliferation assay (Ki-67LI and mitotic scores) and HER2 status
Variable BCSS DMFS
Number exposed to
risk
Number of
events
Proportion
surviving
Number exposed to
risk
Number of
events
Proportion
surviving
Ki-67LI
Low 295 28 90.5% 295 46 84.4%
Moderate 250 68 72.8% 249 77 69.7%
High 95 43 54.7% 94 50 46.8%
Mitotic score
1 324 39 88% 324 58 82%
2 156 36 77% 155 46 70.3%
3 226 93 58.8% 225 101 55%
HER2 status
Negative 622 136 78.1% 620 170 72.5%
Positive 66 29 56% 66 32 51.5%
BCSS, Breast cancer-specific survival; DMFS, distant metastasis-free survival.
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assessed by using full-face sections to avoid missing the
hot spot and to provide data that can be used in routine
practice rather than TMA, which is currently a research
tool. Although some research studies of Ki-67LI have
reported correlation between Ki-67LI assessed on TMA
or needle-core biopsy [37] and that assessed on full-face
sections, these correlations are not absolute, and discre-
pant cases exist. The results of the current study sup-
port other studies that demonstrated that Ki-67LI
should be assessed in the most active areas (hot spots),
a method that has also been used and validated in the
assessment of mitotic counts [21].
The majority of HER2+ and TN tumors are known to
be poorly differentiated and highly proliferative [2]. No
association between MS and outcome could be identi-
fied in either HER2+ or TN classes. None of the pre-
viously reported Ki-67LI cut-off points was able to
stratify HER2+ or TN tumors into clinically relevant
subclasses. Although the high Ki-67LI cut-off generated
in HER2+ and TN training sets appeared to stratify
these tumors into proliferative subgroups based on out-
come, no association with survival was identified in the
validation sets. These findings could be explained by the
small number of cases in these molecular classes after
splitting them into training and validation sets or by
their high proliferation rate, which limits the ability of a
proliferation marker to identify clinically distinct
subclasses.
The number of sections from each case required to
assess Ki-67LI reliably in a clinical laboratory setting
also was addressed. The results obtained from each of
four sections assessed per tumor showed a high level of
concordance, indicating that using a single FFS/case
appears appropriate and representative.
It is important, however, to mention that in the cur-
rent study, outcome was assessed in a context in which
the treatment given may not be homogeneous, and
indeed, in some cases, the parameter being addressed
(mitotic score as a grading component) may have
affected the original systemic treatment decision. This
may limit the ability of the prognostic analyses in mak-
ing assertions that either mitotic counts or Ki-67LI can
identify a group in which chemotherapy could be
withheld.
Conclusion
In conclusion, proliferation assessment by using Ki-67LI
and MS can distinguish subgroups of patients with
luminal/HR+ BC with significantly different clinical out-
comes. Overall, both showed comparable results, with
Ki-67LI having a marginal advantage in terms of
patient-cohort separation. Neither MS nor Ki-67LI has
additional prognostic value in HER2+ and TNBC. This
study emphasises the importance of determination of
appropriate clinically relevant cut points for Ki-67LI and
demonstrates that sufficient IHC assessment of Ki-67LI
can be achieved by using a single FFS. This method
could provide a cost-effective method for prognostic
subclassification of luminal/HR+ BC in routine clinical
practice.
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